WallStreetZenWallStreetZen

NYSE: NVS
Novartis Ag Earnings Dates, Reports, Calls

OverviewForecastEarnings
RevenueDividendOwnership
Novartis Ag earnings were $12.9B for the trailing 12 months ending Mar 31, 2025, with -12.6% growth year over year. The latest NVS earnings report on Mar 31, 2025 announced Q1 2025 earnings of $3.6B, up 28% from last quarter. For the last reported fiscal year 2024 ending Dec 31, 2024, NVS reported annual earnings of $11.9B, with -19.6% growth. The next NVS earnings date is Jul 17, 2025.

NVS past earnings growth

How has NVS's earnings growth performed historically?

Company
-12.62%
Industry
111.61%
Market
36.45%
NVS's earnings have grown slower... subscribe to Premium to read more.
Earnings Growth vs Industry Performance
NVS's earnings have grown slower... subscribe to Premium to read more.
Earnings Growth vs Market Performance
NVS's earnings growth is slowing... subscribe to Premium to read more.
Accelerating Earnings Growth Performance

NVS earnings history

Current Revenue
$53.2B
Current Earnings
$12.9B
Current Profit Margin
24.2%
NVS's has not demonstrated consistent... subscribe to Premium to read more.
Long-term Earnings Growth Trend Performance

NVS Return on Equity

Current Company
30.7%
Current Industry
53.5%
Current Market
28.6%
NVS's Return on Equity (30.7%)... subscribe to Premium to read more.
High Return on Equity Performance

NVS undefined

Current Company
12.8%
Current Industry
10.1%
NVS is generating higher Return... subscribe to Premium to read more.
Above Average Return on Assets Performance

Be the first to know when NVS announces earnings.

NVS undefined

Current Company
23.38%
Current Industry
17.1%
NVS's ability to generate Return... subscribe to Premium to read more.
Increasing Return on Capital Employed Performance

NVS vs General Drug Manufacturer Stocks

TickerEBITDAEarningsY/Y EarningsEPS
NVS$26.42B$12.86B+3.93%$6.44
AZN$17.68B$7.77B+34.22%$2.51
MRK$26.05B$17.43B+11.60%$6.89
AMGN$15.28B$5.93B-2.97%$11.05
SNY$11.90B$5.79B+13.35%$2.31
View Top General Drug Manufacturer Stocks

NVS earnings dates

Next earnings date
Jul 17, 2025

Novartis Ag Earnings Reports & History FAQ

What were Novartis Ag's earnings last quarter?

On NVS's earnings call on Invalid Date, Novartis Ag (NYSE: NVS) reported Q1 2025 earnings per share (EPS) of $1.83, up 39.69% year over year. Total NVS earnings for the quarter were $3.61 billion. In the same quarter last year, Novartis Ag's earnings per share (EPS) was $1.31.

If you're new to stock investing, here's how to buy Novartis Ag stock.

When does Novartis Ag report earnings?

The next NVS earnings call is Invalid Date. Add NVS to your watchlist to be reminded of Novartis Ag's next earnings date.

What was NVS's earnings growth in the past year?

As of Novartis Ag's earnings date in Invalid Date, Novartis Ag's earnings has grown -12.62% year over year. This is 124.23 percentage points lower than the US Drug Manufacturers - General industry earnings growth rate of 111.61%. NVS earnings in the past year totalled $12.86 billion.

Is Novartis Ag profitable or losing money?

As of the last Novartis Ag earnings report, Novartis Ag is currently profitable. Novartis Ag's net profit (also called net income) for the twelve months ending Mar 31, 2025 was $12.86 billion, a 15.65% decrease year over year.
©2025 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.